Dr. Randeep Guleria explained how COVID-19 patients are treated.
New Delhi:
Remdesivir Helps Reduce Hospital Stay, But Benefits Are Not Reflected In Death And Death Benefits, Dr. Randeep Guleria, Director Of The Indian Institute Of Medical Sciences (AIIMS), Said Friday .
“There is no defined anti-viral drug that has been proven with respect to COVID-19. A lot of research is going on. There are anti-viral drugs that are being used, one of them is “Remdesivir” “which is made by a company from the United States. The data suggests that this helps reduce the hospital stay, but it shows no benefit when it comes to death or death benefits. So we need more data to suggest whether these drugs are helpful or not, “said Dr. Guleria in an interview with ANI.
“Remdesivir is being used in accordance with the emergency use authorization guidelines. The stock is also very limited. I hope that in the coming weeks we will have larger doses,” he added. .
Dr. Guleria explained how patients with COVID-19 are treated. He said that hydroxychloroquine (HCQ) is the medication commonly used to treat patients.
“The reused drugs are available on the market and studies have also suggested that they may have antiviral activities and therefore that they can be used. The drug we commonly use to treat patients with coronavirus is hydroxychloroquine ( HCQ). There are controversies regarding the drug, but the data suggests that it may be helpful, especially in the early days, “he said.
He then talked about convalescent plasma therapy in which we give plasma with antibodies from people who have recovered to the affected patient so that these antibodies can help fight the virus.
“These treatments are still evolving and some may be useful and others may not be. But the treatment currently remains supportive oxygenation. Up to 90 to 95 percent of patients with good oxygenation supportive care recovers and becomes well, “he added. .
(With the exception of the title, this story was not edited by GalacticGaming staff and is published from a syndicated feed.)
